

UNITED STATES PARTMENT OF COMMERCE United States Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO.

09/589, 395 06/07/00 ASHKENAZI A P1759R1

HM12/0720

HM12/0/2

GENENTECH INC ATTN DIANE L MARSCHANG 1 DNA WAY SOUTH SAN FRANCISCO CA 94080 EXAMINER

NICKOL,G

ART UNIT PAPER NUMBER

1642

DATE MAILED:

07/20/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

•		Applicatio	n No.	Applicant(s)	
		09/589,39	5	ASHKENAZI ET AL.	
	Offic Action Summary	Examiner		Art Unit	
		Gary B. Nic	kol Ph.D.	1642	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status					
1)	Responsive to communication(s) filed on	·			
2a)□		— nis action is i	non-final.		
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition	on of Claims				
4) Claim(s) 1-18 is/are pending in the application.					
4	a) Of the above claim(s) is/are withdra	wn from cor	sideration.		
5)	Claim(s) is/are allowed.		•		
6)	6) Claim(s) is/are rejected.				
7)	Claim(s) is/are objected to.				
8)🖾	Claim(s) 1-18 are subject to restriction and/or	election req	uirement.		
Application	on Papers			•	
9) The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Pri rity under 35 U.S.C. §§ 119 and 120					
,	13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
. a)[a) All b) Some * c) None of:				
	1. Certified copies of the priority documents have been received.				
	2. Certified copies of the priority documents have been received in Application No				
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
1	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).				
a	a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.				
Attachmen		· •		•	
2) Notic	te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	· · ·		y (PTO-413) Paper No(s) Patent Application (PTO-152)	

number to responses to Written Restrictions.

Art Unit: 1642

DETAILED ACTION

Claims 1-18 are pending in the application and are currently under prosecution.

Please Note: In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-308-4315.

A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program. If you have any questions or suggestions please contact Anthony Caputa, Ph.D., Supervisory Patent Examiner at 703-308-3995. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-5, 10-13, drawn to a method of inducing apoptosis in mammalian cancer cells comprising exposing cancer cells to an anti-DR4 receptor antibody, classified in class 435, subclass 7.23.
- II. Claims 1,6-13 drawn to a method of inducing apoptosis in mammalian cancer cells comprising exposing cancer cells to an anti-DR5 receptor antibody, classified in class 435, subclass 7.23.

Art Unit: 1642

- III. Claims 14-15 drawn to a method of treating cancer in a mammal comprising administering an anti-DR4 receptor antibody, classified in class 424, subclass 143.1.
- IV. Claims 14,16 drawn to a method of treating cancer in a mammal comprising administering an anti-DR5 receptor antibody, classified in class 424, subclass 143.1.
- V. Claim 17 drawn to a composition comprising an agonistic anti-Apo-2 ligand receptor antibody and CPT-11 in a carrier, classified in class 530, subclass 387.1.
- VI. Claim 18 drawn to a kit comprising agonistic anti-Apo-2 ligand receptor antibody and CPT-11 and instructions for use, classified in class 435, subclass 810.

The inventions are distinct, each from the other because of the following reasons:

The inventions of Groups I-IV are *materially distinct* methods which differ at least in objectives, method steps, reagents and/or dosages and/or schedules used, response variables, and criteria for success. Likewise, the inventions of Groups V and VI represent *materially distinct* products with different classifications.

The inventions of Groups V and Groups I-IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (I) the

Art Unit: 1642

process for using the product as claimed can be practiced with another materially different product or (ii) the product as claimed can be used in a materially different process of using that product [see MPEP § 806.05(h)]. In the instant case the antibody product as claimed can be used in a materially different process such as affinity chromatography.

The inventions of Groups VI and Groups I-IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (I) the process for using the product as claimed can be practiced with another materially different product or (ii) the product as claimed can be used in a materially different process of using that product [see MPEP § 806.05(h)]. In the instant case the kit /antibody product as claimed can be used in a materially different process such as affinity chromatography.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper. Furthermore, because these inventions are distinct for the reasons given above and the search required for one group is not required for another group, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Art Unit: 1642

application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gary B. Nickol Ph.D. whose telephone number is 703-305-7143. The examiner can normally be reached on M-F, 8:30-5:00 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Gary B. Nickol, Ph.D. Examiner
Art Unit 1642

GBN July 16, 2001

ANTHONY C. CAPUTA SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600



RESTRICTION ELECTION FACSIMILE TRANSMISSION

DATE:
FROM/ATTORNEY:
FIRM:
PAGES, INCLUDING COVERSHEET:
PHONE NUMBER:
TO EXAMINER:
ART UNIT:
SERIAL NUMBER:
FAX/TELECOPIER NUMBER: (703) 308-4315
PLEASE NOTE: THIS FACSIMILE NUMBER IS TO BE USED <u>ONLY</u> FOR RESPONSES TO RESTRICTIONS.
COMMENTS:
THE RESERVE TO A DESTREE TO A DISTANCE CONTACT THE ATTORNEY AT THE

IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 1096-OG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SHOULD BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR, PLEASE NOTIFY THE ATTORNEY LISTED HEREON IMMEDIATELY.